//
E. Camilleri
N. van Rein
O. Dekkers
R. Feelders
M. Huisman
M. Kaya
F. Klok
A. Pereira
F. Rosendaal
F. Shokri
S. Cannegieter
Leiden University Medical Centre, Leiden, Netherlands
Department of Medicine, Division of Endocrinology and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Department of Medicine, Division of Endocrinology and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Department of Medicine – Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
,Leiden University Medical Center, Leiden, The Netherlands, Leiden, Zuid-Holland, Netherlands
Department of Medicine, Division of Endocrinology and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands, Leiden, Zuid-Holland, Netherlands
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
1VarmX, Leiden, The Netherlands. 2Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands., Leiden, Zuid-Holland, Netherlands
Netherlands
N/A
Cardiovascular (CVS)
Pulmonary/Respiratory Diseases
Blood/haematological Diseases
Venous thrombosis
Fibrinogen
von Willebrand factor
Glucocorticoid
Fibrinogen (IV)
Evithrom
FVIII
N/A
N/A
NA
N/A
N/A
N/A